PCVX Relative Valuation
PCVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCVX is overvalued; if below, it's undervalued.
Historical Valuation
Vaxcyte Inc (PCVX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -12.77. The fair price of Vaxcyte Inc (PCVX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：32.00
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.29
P/B
Median3y
3.97
Median5y
4.04
-13.84
FCF Yield
Median3y
-6.54
Median5y
-6.36
Competitors Valuation Multiple
The average P/S ratio for PCVX's competitors is 50.60, providing a benchmark for relative valuation. Vaxcyte Inc Corp (PCVX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Vaxcyte Inc (PCVX) currently overvalued or undervalued?
What is Vaxcyte Inc (PCVX) fair value?
How does PCVX's valuation metrics compare to the industry average?
What is the current P/B ratio for Vaxcyte Inc (PCVX) as of Jul 08 2025?
What is the current FCF Yield for Vaxcyte Inc (PCVX) as of Jul 08 2025?
What is the current Forward P/E ratio for Vaxcyte Inc (PCVX) as of Jul 08 2025?